Dennis Condon Net Worth

The estimated Net Worth of Dennis E Condon is at least $369 Mille dollars as of 22 March 2022. Mr. Condon owns over 9,000 units of Establishment Labs Inc stock worth over $368,910 and over the last 5 years he sold ESTA stock worth over $0. In addition, he makes $0 as Independent Director at Establishment Labs Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Condon ESTA stock SEC Form 4 insiders trading

Dennis has made over 3 trades of the Establishment Labs Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 9,000 units of ESTA stock worth $91,710 on 22 March 2022.

The largest trade he's ever made was exercising 9,000 units of Establishment Labs Inc stock on 22 March 2022 worth over $91,710. On average, Dennis trades about 2,455 units every 26 days since 2019. As of 22 March 2022 he still owns at least 9,000 units of Establishment Labs Inc stock.

You can see the complete history of Mr. Condon stock trades at the bottom of the page.

Dennis Condon biography

Dennis E. Condon serves as Independent Director of the Company. He was President and Chief Executive Officer of Merz Aethetics (formerly BioForm Medical) from July 2007 to January 2013. From March 2006 to May 2007, Mr. Condon was President and Chief Executive Officer of Aspara Medical, and was President and Chief Executive Officer of Reliant Technology from January 2005 to February 2006. Prior to joining Reliant Technology, Mr. Condon held various roles at Spa Medicus, The Plastic Surgery Company and Mentor Corporation. Mr. Condon has served on the Board of Directors of Suneva Medical since September 2016 and AirXpanders Inc from 2012 to July 2019. Mr. Condon holds a bachelor’s degree in Biological Science from University of California, Davis.

How old is Dennis Condon?

Dennis Condon is 83, he's been the Independent Director of Establishment Labs Inc since 2017. There are no older and 17 younger executives at Establishment Labs Inc.

What's Dennis Condon's mailing address?

Dennis's mailing address filed with the SEC is C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES, DE, 19958.

Insiders trading at Establishment Labs Inc

Over the last 6 years, insiders at Establishment Labs Inc have traded over $8,492,826 worth of Establishment Labs Inc stock and bought 169,894 units worth $9,905,657 . The most active insiders traders include David Hung, Nicholas Sheridan Lewin e Quiros Juan Jose Chacon. On average, Establishment Labs Inc executives and independent directors trade stock every 34 days with the average trade being worth of $513,072. The most recent stock trade was executed by Quiros Juan Jose Chacon on 11 July 2024, trading 3,641 units of ESTA stock currently worth $163,991.

What does Establishment Labs Inc do?

establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.

Complete history of Mr. Condon stock trades at Establishment Labs Inc

Establishment Labs Inc executives and stock owners

Establishment Labs Inc executives and other stock owners filed with the SEC include:

• Juan Jose Chacon Quiros,
  Founder, CEO & Exec. Director
• Juan Jose Chacon Quiros,
  Chief Executive Officer, Director
• Salvador Santos Dada,
  Chief Operating Officer (Medical Leave of Absence)
• Renee Gaeta,
  Chief Financial Officer
• Salvador Santos,
  Chief Operating Officer
• Eddie De Oliveira,
  Vice President of Sales Latin America
• David Erickson,
  IR Contact Officer
• Edward Schutter,
  Independent Director
• David Hung,
  Independent Director
• Lisa Gersh,
  Independent Director
• Dennis Condon,
  Independent Director
• Lisa Colleran,
  Independent Director
• Jeremy Livianu,
  General Counsel
• Alberto Quesada,
  Vice President - Quality & OUS Regulatory Affairs
• Roberto De Mezerville,
  Chief Technology Officer
• Nicholas Lewin,
  Chairman of the Board
• Roberto de Mezerville,
  Chief Technology Officer
• Rosalyn Cole d'Incelli,
  VP of Clinical & Medical Affairs
• Eddie De Oliveira,
  VP of Sales, Brazil
• Dr. Heather Brennan,
  Head of U.S. Commercial Operations
• Jeffrey Clark Bettinger,
  Global Head of People
• Neeta Toprani,
  Gen. Counsel & Corp. Sec.
• Roberto De Mezerville,
  Chief Technology Officer
• Pratip Dastidar,
  Head of Global Operations
• Rajbir Singh Denhoy,
  CFO and Head of Strategy & Investor Relations
• Paul D. Rodio,
  Chief Operating Officer
• Tu, Lp Cph,
  10% owner
• Asset Management, Llcjw Par...,
  
• Pratip Dastidar,
  Head of Global Operations
• Ann Custin,
  Director
• Bryan Slotkin,
  Director
• Leslie Gillin,
  Director
• Raj Denhoy,
  Chief Financial Officer
• Samuel Ross Mansbach,
  
• Filippo Caldini,
  President